Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
Controversies in Iron Chelation in Myelodysplastic Syndromes
Clinicians attempting to manage iron overload in their patients with MDS are faced with a variety of guidelines that may reflect differing expert opinions. In this program, Dr. Giagounidis and Dr. Leitch discuss some of the controversies surrounding the importance and treatment of iron overload in this patient population, including whether iron overload has a significant impact on the health of the MDS patients, the possible benefits of iron chelation on survival, on decreasing AML transformation, and/or on improving hematologic parameters, and which MDS patients are appropriate for iron chelation therapy.
|
|
Faculty
|
|
|
Aristoteles A.N. Giagounidis, MD, PhD
Head of Clinical Research Unit
St. Johannes Hospital
Medizinische Klinik II
Duisburg, Germany
|
|
|
|
Heather A. Leitch, MD, PhD, FRCPC
Hematologist
Department of Medicine, Division of Hematology
St. Paul’s Hospital
University of British Columbia
Vancouver, British Columbia, Canada
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Assess the role of iron chelation therapy in improving survival in MDS patients identified as appropriate for treatment.
- Based on recent guidelines for the treatment of iron overload in patients with MDS, identify your MDS patients who meet treatment criteria and are likely to benefit from iron chelation therapy.
|
Disclosure Information
| |
Aristoteles A.N. Giagounidis, MD, PhD, is on the speakers bureau of Celgene Corporation; is on advisory boards for Novartis Pharmaceuticals Corporation and Pharmion Corporation; and is a stock shareholder in Hoffmann-La Roche Inc.
Heather A. Leitch, MD, PhD, FRCPC, is a consultant for and on the speakers bureau of Novartis Pharmaceuticals Corporation.
|
|
|
|
|
|
|
